In the forefront of cancer treatment research, precise and comprehensive data resources play a decisive role in the development of anti-tumor drugs. As a novel anti-cancer tool, nucleic acid-based drugs leverage the unique biological properties of nucleic acid molecules to precisely interfere with critical life processes of cancer cells, such as gene expression and signal transduction, offering new hope for combating cancer. However, the development of such drugs faces numerous challenges, from nucleic acid sequence design and carrier construction to preclinical and clinical studies. Each step requires extensive experimental data and in-depth mechanistic analysis.
The Anti-Tumor Nucleic Acid Drug Database is a critical auxiliary tool designed to address these challenges. It extensively compiles research findings on various nucleic acid-based anti-tumor drugs, including a wide range of screened nucleic acid sequences, carrier types, and related compound information. The database provides in-depth analyses of drug targets, such as cancer-specific genes and regulatory proteins, along with detailed evaluations of their activity in multiple cancer cell lines (e.g., MCF-7, PC-3, SK-BR-3). It also explores mechanisms of action, such as how these drugs influence cancer cell proliferation, apoptosis, and metastasis.
To date, the database has cataloged information on over 100 nucleic acid-based drugs with potential anti-tumor activityBy utilizing this database, researchers can swiftly access key data to establish a solid theoretical foundation for developing novel anti-tumor nucleic acid drugs, significantly shortening development cycles and reducing costs. This not only accelerates the translation of laboratory discoveries into clinical applications but also holds promise for providing cancer patients with more effective treatment options, improving their quality of life and survival rates, and driving sustained progress in the field of oncology.
